Modernization of Traditional Chinese Medicine is a longstanding priority in China’s healthcare policy. The “Healthy China 2030” plan explicitly calls for “inheriting and developing TCM”; the National Administration of Traditional Chinese Medicine continues advancing major TCM revitalization programs. But TCM modernization is not only a policy question — it’s also a methodological debate in the global medical community about how to scientifically validate traditional empirical knowledge.
## Core Challenges of TCM Modernization
**Syndrome standardization**: TCM diagnosis centers on “syndromes” (zhèng hòu — e.g., “liver-kidney yin deficiency,” “qi deficiency with blood stasis”), but syndrome definitions vary significantly across practitioners, lacking operational objective indicators — severely limiting clinical research reproducibility. AI-assisted tongue image analysis (inspection diagnosis) and digitized pulse sensing (pulse diagnosis) are attempting to objectify subjective diagnosis.
**Compound formula research methodology**: Chinese medicine predominantly uses multi-herb formulas; conventional RCT design faces the dilemma of “deconstructing the formula” versus “preserving holistic effects.” Network Pharmacology — computationally simulating interaction networks between herbal components and target proteins — has become the mainstream method for formula mechanism research.
**International regulatory barriers**: the FDA (US) and EMA (EU) require botanical drugs to meet the same safety and efficacy standards as chemical drugs; pathways for Chinese patent medicines entering international markets are extremely limited. WHO’s 11th revision of the International Classification of Diseases (ICD-11), which first included a Traditional Medicine chapter, represents significant progress.
## Successful Scientific Validation Cases
**Artemisinin**: Tu Youyou extracted artemisinin from the traditional herb Artemisia annua, developing it into an effective antimalarial drug and winning the 2015 Nobel Prize in Physiology or Medicine — the most important TCM modernization success case, demonstrating the viability of finding modern drugs from traditional medicines.
**Berberine**: extracted from Coptis chinensis (Huang Lian), modern research has proven it possesses multiple pharmacological actions including blood glucose reduction, gut microbiome regulation, and antitumor effects — entering multiple international clinical trials.
**Lianhua Qingwen**: a Lingnan TCM compound formula widely used during COVID-19 after inclusion in China’s COVID treatment guidelines; multiple real-world studies and RCTs have since been conducted (some published in Phytomedicine and the Journal of Ethnopharmacology), though controversy persists.
## Emerging Technology Tools
AI and big data are enabling TCM modernization: NLP mining ancient texts (Compendium of Materia Medica) for prescription-herb patterns; machine learning building syndrome-formula-outcome prediction models; metabolomics and proteomics elucidating the systems biology mechanisms of TCM active compounds.
See [TCM Active Compound Research](https://sunqi.org/tcm-active-compounds-en/) and [WHO Traditional Medicine Strategy 2025](https://www.who.int/publications/i/item/9789240006263).
